Market Closed -
Nasdaq
04:00:00 2024-07-08 pm EDT
|
5-day change
|
1st Jan Change
|
1.27
USD
|
-3.79%
|
|
-5.93%
|
-48.37%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,145
|
723.1
|
390.7
|
117.9
|
63.51
|
-
|
-
|
Enterprise Value (EV)
1 |
907
|
478.1
|
175.2
|
117.9
|
63.51
|
63.51
|
63.51
|
P/E ratio
|
-30.5
x
|
-7.11
x
|
-3.01
x
|
-0.95
x
|
-0.82
x
|
-0.89
x
|
-0.81
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,669
x
|
2,892
x
|
-
|
-
|
-
|
-
|
9.67
x
|
EV / Revenue
|
2,669
x
|
2,892
x
|
-
|
-
|
-
|
-
|
9.67
x
|
EV / EBITDA
|
-39.4
x
|
-7.6
x
|
-3.65
x
|
-0.92
x
|
-0.65
x
|
-0.58
x
|
-
|
EV / FCF
|
-31
x
|
-11.5
x
|
-4.31
x
|
-1.13
x
|
-0.73
x
|
-0.58
x
|
-0.47
x
|
FCF Yield
|
-3.23%
|
-8.73%
|
-23.2%
|
-88.3%
|
-137%
|
-173%
|
-211%
|
Price to Book
|
5.21
x
|
-3.64
x
|
-1.1
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
33,664
|
36,836
|
47,352
|
47,936
|
48,116
|
-
|
-
|
Reference price
2 |
34.01
|
19.63
|
8.250
|
2.460
|
1.320
|
1.320
|
1.320
|
Announcement Date
|
3/24/21
|
2/28/22
|
3/23/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5.2
|
0.429
|
0.25
|
-
|
-
|
-
|
-
|
6.567
|
EBITDA
1 |
-
|
-29.09
|
-95.11
|
-106.9
|
-128.5
|
-97.43
|
-110
|
-
|
EBIT
1 |
-
|
-30.1
|
-96.44
|
-108.1
|
-129.7
|
-92.15
|
-116
|
-139.9
|
Operating Margin
|
-
|
-7,016.08%
|
-38,576%
|
-
|
-
|
-
|
-
|
-2,129.82%
|
Earnings before Tax (EBT)
1 |
-
|
-35.85
|
-95.4
|
-106.5
|
-123.5
|
-88.81
|
-113.2
|
-137.7
|
Net income
1 |
-
|
-35.85
|
-95.4
|
-106.5
|
-123.5
|
-88.81
|
-113.2
|
-137.7
|
Net margin
|
-
|
-8,357.34%
|
-38,160.8%
|
-
|
-
|
-
|
-
|
-2,097.33%
|
EPS
2 |
-0.5300
|
-1.114
|
-2.760
|
-2.740
|
-2.580
|
-1.615
|
-1.479
|
-1.620
|
Free Cash Flow
1 |
-
|
-36.92
|
-63.14
|
-90.69
|
-104.1
|
-87
|
-109.9
|
-134.2
|
FCF margin
|
-
|
-8,606.99%
|
-25,255.2%
|
-
|
-
|
-
|
-
|
-2,043.65%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/6/20
|
3/24/21
|
2/28/22
|
3/23/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-23.17
|
-24.03
|
-28.77
|
-25.88
|
-28.26
|
-28.64
|
-36.32
|
-34.75
|
-
|
-24.22
|
-25
|
-26
|
-22
|
-
|
-
|
EBIT
1 |
-23.49
|
-24.35
|
-29.06
|
-26.18
|
-28.56
|
-28.93
|
-37.2
|
-35.02
|
-28.54
|
-24.46
|
-23.3
|
-22.73
|
-21.6
|
-25.29
|
-27.95
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-23.39
|
-24.25
|
-28.91
|
-25.78
|
-27.54
|
-27.46
|
-35.75
|
-33.32
|
-26.92
|
-23.23
|
-22.62
|
-22.09
|
-20.94
|
-25.29
|
-27.95
|
Net income
1 |
-23.39
|
-24.25
|
-28.91
|
-25.78
|
-27.54
|
-27.46
|
-35.75
|
-33.32
|
-26.92
|
-23.23
|
-22.62
|
-22.09
|
-20.94
|
-25.29
|
-27.95
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6300
|
-0.6500
|
-0.7700
|
-0.6900
|
-0.6300
|
-0.5800
|
-0.7500
|
-0.7000
|
-0.5600
|
-0.4800
|
-0.4377
|
-0.3796
|
-0.3373
|
-0.3850
|
-0.4050
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/4/22
|
8/9/22
|
11/3/22
|
3/23/23
|
5/11/23
|
8/1/23
|
11/7/23
|
3/26/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
238
|
245
|
216
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-36.9
|
-63.1
|
-90.7
|
-104
|
-87
|
-110
|
-134
|
ROE (net income / shareholders' equity)
|
-
|
-46.6%
|
-45.3%
|
-54.4%
|
-98.4%
|
-124%
|
-157%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-28.2%
|
-38.2%
|
-44.4%
|
-71.5%
|
-87.6%
|
-130%
|
-
|
Assets
1 |
-
|
127.1
|
249.7
|
240.1
|
172.7
|
101.4
|
87.11
|
-
|
Book Value Per Share
|
-
|
6.530
|
-5.390
|
-7.520
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-1.130
|
-1.800
|
-2.320
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.59
|
0.92
|
0.27
|
0.1
|
-
|
-
|
-
|
Capex / Sales
|
-
|
137.53%
|
369.6%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/6/20
|
3/24/21
|
2/28/22
|
3/23/23
|
3/26/24
|
-
|
-
|
-
|
Last Close Price
1.32
USD Average target price
10.67
USD Spread / Average Target +708.08% Consensus |
1st Jan change
|
Capi.
|
---|
| -48.37% | 63.51M | | +17.09% | 45.34B | | +42.10% | 40.42B | | -9.70% | 37.92B | | +33.28% | 31.75B | | -8.98% | 27.71B | | +13.37% | 26.52B | | +44.11% | 13.96B | | +32.33% | 12.44B | | -7.26% | 11.26B |
Other Biotechnology & Medical Research
|